Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer

• Status: Unknown status
• Trial end date: 2020-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the effect and toxicity of intrapleural administration of hypertonic cisplatin for malignant pleural effusion in patients with non-small-cell lung cancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shantou University Medical College
• Treatments: Cisplatin

Criteria

Inclusion Criteria:

• Cytologically proven and previously untreated malignant pleural effusion of Non-small-cell Lung Cancer;

• An Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1;

• A leucocyte count of≥4000µl;

• A platelet count of≥100000µl;

• A normal creatinine level;

• Serum glutamic oxaloacetic transaminase/glutamic pyruvic transaminase levels of no more than twice the upper limit of normal;

• Survival time ≥12 weeks.

Exclusion Criteria:

• Previously treated malignant pleural effusion;

• Pericardial effusion；

• Pregnant；

• Uncontrolled hypertension or diabetes；

• Liver cihrosis.